<；P>；PROBLEM TO BE SOLVED: To provide a method for screening an adjuvant of a mucosa vaccine obtaining a double barrier function in mucous membrane surface and in a living body by activating mucosa immunity with an administration from the mucous membrane such as an peroral or trans-nasal administration. <；P>；SOLUTION: This method for screening the adjuvant of the mucosa vaccine is provided by incubating a wild type non-human animal-derived CD11c+ intestinal tract lamina propia cells (LPC) with flagellin derived from flagellum bacteria or the flagellum derived from the flagellum bacteria in the presence or absence of a test substance in vitro to make them in contact with each other, measuring the concentration of IL-6 and/or IL-12p40 in supernatant, and selecting by using the elevation of the measured concentration of the IL-6 and/or IL-12p40 in the presence of the test substance as compared with that in the absence of the test substance as an index, or also administering the flagellum bacteria and test substance orally to the wild type non-human animal, measuring the number of the flagellum bacteria in its mesenteric lymph node (MLN) and selecting the reduction of the number of the flagellum bacteria as compared with the case of administering only the flagellum bacteria perorally, as an index. <；P>；COPYRIGHT: (C)2008,JPO&INPIT
